Article

IL-33 can promote survival, adhesion and cytokine production in human mast cells.

Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305-5324, USA.
Laboratory Investigation (Impact Factor: 3.83). 11/2007; 87(10):971-8. DOI: 10.1038/labinvest.3700663
Source: PubMed

ABSTRACT IL-33 is a recently identified member of the IL-1 family of molecules, which also includes IL-1 and IL-18. IL-33 binds to the receptor, T1/ST2/IL-1R4, and can promote cytokine secretion by Th2 cells and NF-kappaB phosphorylation in mouse mast cells. However, the effects of these molecules, especially IL-33, in human mast cells are poorly understood. Expression of the receptors for IL-1 family molecules, specifically, IL-1R1, IL-18R and T1/ST2, was detectable intracellularly in human umbilical cord blood-derived mast cells (HUCBMCs) by flow cytometry, but was scarcely detectable on the cells' surface. However, IL-1beta, IL-18 or IL-33 induced phosphorylation of Erk, p38 and JNK in naïve HUCBMCs, and IL-33 or IL-1beta, but not IL-18, enhanced the survival of naive HUCBMCs and promoted their adhesion to fibronectin. IL-33 or IL-1beta also induced IL-8 and IL-13 production in naïve HUCBMCs, and enhanced production of these cytokines in IgE/anti-IgE-stimulated HUCBMCs, without enhancing secretion of either PGD(2) or histamine. Moreover, IL-33-mediated IL-8 production by HUCBMCs was markedly reduced by the p38 MAPK inhibitor, SB203580. In contrast to findings with mouse mast cells, IL-18 neither induced nor enhanced secretion of the mediators PGD(2) or histamine by HUCBMCs. Our findings identify previously unknown functions of IL-33 in human mast cells. One of these is that IL-33, like IL-1beta, can induce cytokine production in human mast cells even in the absence of stimuli of FcepsilonRI aggregation. Our findings thus support the hypothesis that IL-33 may enhance mast cell function in allergic disorders and other settings, either in the presence or absence of co-stimulation of mast cells via IgE/antigen-FcepsilonRI signals.

0 Bookmarks
 · 
122 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Amastigotes from L(L) amazonensis (La); L(L) venezuelensis (Lv); L(V) brasiliensis (Lb) and L(L)chagasi(Lch) were cultured axenically in a liquid culture medium (O’Daly’s medium). Patients from a cutaneous leishmaniasis (CL) endemic and hyperendemic regions in Venezuela, receiving different treatments were followed up for 6 years. Remission of lesions (weeks) were: Spontaneous remission (SR): 7; Glucantime® (Glu) chemotherapy: 9; Immunotherapy with La, Lv, Lb, Lch amastigotes Tosyl-Lysil-Chloromethyl-Ketone (TLCK) treated and Nonidet P-40 (NP-40) extracted (AS100-1VT): 7. While vaccinating subjects for CL protection, we observed 100% clinical remission of a psoriatic lesion in one subject. In an open trial, 2,770 subjects showed baseline psoriasis area and severity index (PASI) compared with post-treatment values as follows: PASI 100, 23%; PASI 75, 45%; PASI 50, 13%; PASI 10, 9% and <PASI 10, 3% of patients, without serious adverse events. Similar results were obtained with AS100-2 La, Lv, Lb and Lch monovalent vaccines. After treatment with AS100-1VT, subjects with psoriatic arthritis (PsA) decreased in arthritis score, tender joints counts and nail changes; the highest decreased in the PASI 100 group. The vaccines induced cellular immunity with absence of humoral antibody responses. Lymphocyte subsets (LS) in peripheral blood mononuclear cells (PBMC) decrease as PASI increased migrating from the blood to the skin/joints. After vaccine treatment the LS migration is stopped explaining remission of lesions. Purified Leishmania antigenic fractions (AS200) induced linear delayed type hypersensitivity reactions (DTH) in guinea pigs. A DBA-1 mouse collagen induced arthritis (CIA) model with AS200 treatment had the least amount of forepaw inflammation and the lowest arthritis scores, lower than dexamethasone. The vaccines AS100-1VT, AS100-2 and AS200 were not immunosuppressors, but immunomodulators decreasing inflammatory cytokines. The aim of this review is to explain the serendipity discovery of leishmania parasites inducing remission of psoriasis and related diseases, unprecedented discovery in the scientific literature.
    British Journal of Medicine & Medical Research. 09/2014; 5(1):1-22.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Immunization of mice or rats with a "non-self" protein is a commonly used method to obtain monoclonal antibodies, and relies on the immune system's ability to recognize the immunogen as foreign. Immunization of an antigen with 100% identity to the endogenous protein, however, will not elicit a robust immune response. To develop antibodies to mouse proteins, we focussed on the potential for breaking such immune tolerance by genetically fusing two independent T-cell epitope-containing sequences (from tetanus toxin (TT) and diphtheria toxin fragment A (DTA)) to a mouse protein, mouse ST2 (mST2). Wild-type CD1 mice were immunized with three mST2 tagged proteins (Fc, TT and DTA) and the specific serum response was determined. Only in mice immunized with the T-cell epitope-containing antigens were specific mST2 serum responses detected; hybridomas generated from these mice secreted highly sequence-diverse IgGs that were capable of binding mST2 and inhibiting the interaction of mST2 with its ligand, mouse interleukin (IL)-33 (mIL-33). Of the hundreds of antibodies profiled, we identified five potent antibodies that were able to inhibit IL-33 induced IL-6 release in a mast cell assay; notably one such antibody was sufficiently potent to suppress IL-5 release and eosinophilia infiltration in an Alternaria alternata challenge mouse model of asthma. This study demonstrated, for the first time, that T-cell epitope-containing tags have the ability to break tolerance in wild-type mice to 100% conserved proteins, and it provides a compelling argument for the broader use of this approach to generate antibodies against any mouse protein or conserved orthologue.
    mAbs 12/2014; · 4.73 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective The aim of this study was to clarify the role of IL-33 in tumor progression. Methods Surgical specimens from 81 patients with squamous cell carcinoma of the tongue were studied using immunohistochemistry. Primary tumor sections were analyzed for IL-33 and ST2 expression. To examine the influence of IL-33 on the microenvironment of the tumor, we determined the mast cell density (MCD) and microvessel density of the stroma. Results Patients with high IL-33 expression had a significantly worse prognosis (p = 0.004). IL-33 expression was significantly elevated in patients with local and nodal recurrence (p = 0.014 and p = 0.019). ST2 expression was also associated with a worse prognosis (p = 0.024) and was significantly elevated in patients with nodal recurrence (p = 0.004). MCD was associated with worse prognosis (p = 0.038) and correlated significantly with IL-33 expression (r = 0.626, p < 0.001). Micovessels in the stroma were significantly increased in the high IL-33 group (p < 0.001). Conclusion These data suggest that the IL-33/ST2 axis contributes to tumor aggressiveness and affects the tumor microenvironment. Immunohistochemical evaluation of IL-33 and ST2 is useful for identifying patients at a high risk for poor prognosis.
    Auris Nasus Larynx 12/2014; · 1.00 Impact Factor

Full-text (2 Sources)

Download
19 Downloads
Available from
Nov 4, 2014